GB2539472A — Use of cannabinoids in the treatment of epilepsy

USPTO Abstract

Cannabidiol (CBD) for use in the treatment of focal seizures in Dravet Syndrome is provided. Preferably the focal seizures are focal seizures with impairment and the Dravet Syndrome is treatment-resistant. The CBD may be present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD, less than 0.15% THC and preferably up to 1% cannabidivarin (CBDV). The CBD may also be present as a synthetic compound. Preferably the CBD is for use in combination with one or more concomitant anti-epileptic drugs (AED) selected from the group consisting of carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin and zonisamide, where the number and/or dose of antiepileptic drugs that is/are used in combination with the CBD is reduced. A composition for use in the treatment of epilepsy characterised by focal seizures comprising cannabidiol (CBD), a solvent preferably sesame oil, a co-solvent preferably ethanol, a sweetener preferably sucralose and a flavouring is also provided.